TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04440735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
Study: NCT04606381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-LC-MD
Description: Participants will receive amivantamab admixed with rHuPH20 SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-LC
Description: Participants will receive amivantamab SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC
Description: Participants will receive amivantamab SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC
Description: Participants will receive amivantamab SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC-CF
Description: Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC-CF
Description: Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive lazertinib orally as a film-coated tablet.
Study: NCT02839850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Total Knee Arthroplasty
Description: Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
Study: NCT03424941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI and TAVI
Description: Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CABG and SAVR
Description: Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
Study: NCT04378023

Intervention type: DRUG
Intervention: Neoadjuvant Chemo-radiotherapy
Description: Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.

Intervention type: PROCEDURE
Intervention: Liver Transplantation
Description: If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
Study: NCT04739072

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT05080114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Bakay technique (MT)
Description: The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique (ST)
Description: The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally.
Study: NCT02828046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M281

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03972657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered at the assigned DL by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered at the assigned DL by IV
Study: NCT04349462

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VideoFlurosocopy Swallow Study
Description: VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Water Sip Test
Description: The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
Study: NCT03807219

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnox Comfort
Description: Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04538547

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy
Description: Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Non Accelerated Radiotherapy
Description: Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
Study: NCT03424018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study: NCT01965379

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restriction on food containing phosphorus additives
Description: The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: The control group mantained the usual renal diet oriented prior to the study with a booklet.
Study: NCT01704469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The local anesthetic injection
Study: NCT02354014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (TMC207)
Description: TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR)
Description: Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
Study: NCT03331341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study: NCT04557059

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHa
Description: Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
Study: NCT00295893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02401074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Segmental Bronchoprovocation with Allergen (SBP-Ag)
Description: Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
Study: NCT02043691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Custom Aortic Endograft
Description: The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith t-Branch Endovascular Graft
Description: The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgeon-Modified Endograft
Description: The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
Study: NCT03123289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Gallium citrate PET/CT scan
Description: After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT scan
Description: Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
Study: NCT00321048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Breathing Coordinator
Description: A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
Study: NCT03538483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: 30 ml %0,25 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Inj 0.25%
Description: 20 ml %0,25 bupivacaine
Study: NCT02766621

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PF-06823859
Description: Comparison of different dosages of PF-06823859 to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection SC/IV
Description: Comparison of Placebo to different doses of PF-06823859
Study: NCT00103961

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A behavioral questionnaire will occur at Week 8
Study: NCT01693692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855 Group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855 Group 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03919812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Description: supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
Study: NCT00231907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
Study: NCT01789697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cellular device/computers
Description: A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
Study: NCT02583438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin (Bristol-Myers Squibb Company)
Description: 6-month treatment of Saxagliptin 5mg Qd
Study: NCT00116272

Intervention type: DRUG
Intervention: Etanercept
Description: Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
Study: NCT01769170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03711630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
Study: NCT04961008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bottle-PEP
Description: A device that gives positive pressure from a bottle with the help of a non deflating tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: Routine pulmonary physiotherapy
Study: NCT04490564

Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Kit
Description: Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples

Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 Kit
Description: Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples